Nektar Therapeutics (NKTR) Stock Price & Analysis

Nektar Therapeutics (NKTR) closed at USD 38.55 on Wednesday, October 28, 2026, up 1.53% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 38.55; the Oct 28, 2026 session ranged USD 37.49–38.6 on volume of 404,793 shares. Market capitalization is —, with a 52-week range of USD 33.4–109 (NCM). Source: Nexqual, retrieved October 29, 2026 at 07:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/NKTR.md

Key facts (NKTR)

• Last four reported quarters (through Jun 30, 2026): revenue $54.6M, net income -$157M (-287.8% margin), free cash flow -$234M (SEC filings).
• Insider open-market sales, last ~7 months: 7 Form 4 filings, $2.0M; 4 not under a Rule 10b5-1 plan ($86K); 0 by opportunistic insiders, 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Total return with dividends: 1Y -35.4% vs S&P 500 +13.6%; 5Y -83.0% vs S&P 500 +79.8%.
• Next earnings: 2026-11-12, EPS estimate USD -2.07, revenue estimate $10.4M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NKTR)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (NKTR)

P/S 24.1x · P/B 1.5x · FCF yield -17.78% · Earnings yield -11.94%

Insider sales (SEC Form 4, open-market, last ~7 months) (NKTR)

3 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (NKTR)

Rating changes, last 120 days:

Total return (dividends reinvested) (NKTR)

NKTR earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

NKTR recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

NKTR suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 13, 2026.

NKTR customer concentration

In the period ended Dec 31, 2025, 3 direct customers each accounted for at least 10% (45%, 37%, 14%) of revenue, per the company's 10-K filed Mar 13, 2026. The company does not name them.

NKTR company outlook (results filed Aug 13, 2026)

• “Importantly, our financial position is strong with over one billion dollars in cash and investments at the end of the quarter, and a cash runway that extends into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028.””
• “For further information, visit www.nektar.com and follow us on LinkedIn. 3 Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements which can be identified by words such as: “will”, “develop,” “potential,” “expect”, “may,” “plan” and similar references to future periods.”

Quoted word-for-word from the SEC 8-K results press release.

NKTR analyst estimates and revisions

NKTR options: expected move

Options price a move of about ±15.4% (±$5.90) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 8 reports the stock moved ±2.2% on average.

30-day implied volatility 73.4% vs 92.3% realized over the last 30 trading days. Put/call ratio (volume) 0.05. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 07:23 UTC)

Technical Analysis (NKTR)

Nexqual's technical model rates NKTR "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 07:23 UTC.

Earnings (NKTR)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 07:23 UTC.

Financials & Fundamentals (NKTR)

Source: Nexqual, October 29, 2026 at 07:23 UTC.

Financial Health Score (NKTR)

Nexqual rates Nektar Therapeutics's overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:23 UTC.

Ownership (NKTR)

Source: Nexqual, October 29, 2026 at 07:23 UTC.

From Nektar Therapeutics's Latest SEC 10-K Filing (filed 2026-03-13)

Key Strengths & Strategy (as disclosed to the SEC)

• The FDA and other agencies actively enforce the laws prohibiting the marketing and promotion of off-label uses, and a company that is found to have improperly marketed or promoted off-label use may be subject to significant liability, including criminal and civil penalties under the FDCA and False Claims Act, exclusion from participation in federal healthcare programs, and mandatory compliance programs.
• We previously owned a manufacturing facility in Huntsville, Alabama (the Facility), which manufactured our proprietary polyethylene glycol reagents (PEG reagents) for our PEGylation and advanced polymer conjugate technology operations.
• We developed rezpegaldesleukin and own full rights to this drug candidate.
• If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover an approved product or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit.

Partnerships

• Although we previously entered into a license agreement with Eli Lilly and Company (Lilly) in 2017 (the Lilly Agreement) to develop and commercialize rezpegaldesleukin, on April 23, 2023, we received from Lilly a notice of at-will termination of the Lilly Agreement, and on April 27, 2023, we announced that we would be regaining full rights to rezpegaldesleukin.
• On February 24, 2025, we announced that we had entered into a clinical trial agreement with TrialNet, an international clinical trial network focused on diabetes research, to evaluate rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (TID).

Legal & Regulatory Risks (Item 1A, quoted)

• We or our partners may not obtain regulatory approval for drug candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use.
• Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. We may not be able to obtain orphan drug designation for any indications for our drug candidates, and we may not be able to maintain such designations if granted.
• We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.
• We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt